Merck's doravirine similar to ritonavir-boosted darunavir in Phase III for HIV-1 infection

Merck & Co. Inc. (NYSE:MRK) said once-daily oral doravirine (MK-1439) in combination with other antiretroviral therapies (ARTs) led to viral suppression at week 96 in 73.1% of patients vs. 66% of patients treated with ritonavir-boosted darunavir plus

Read the full 373 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE